Australia-based, but with U.S. aspirations, device specialist Adherium Limited has announced the establishment of a U.S. entity and a Senior VP to look after business development.
Adherium describes itself as a global leader in digital health technologies addressing sub-optimal medication use in chronic disease
The company’s claim to fame is as a provider to pharmaceutical, remote patient monitoring and clinical trials companies. Its proprietary Smartinhaler™ platform comprises a range of approved Smartinhaler™ medication sensors which attach to prescription inhalers, and the SmartinhalerLive™ software, which integrates the data from the Smartinhalers into a usable form via communications protocols, mobile applications and cloud based software. The platform uses wireless technology to provide reminders, monitoring and real-time data collection of inhaler usage for physicians, patients and caregivers to help improve outcomes.
Smartinhaler™ products are approved in the U.S. and were recently approved in Canada. In 2015, Adherium entered a long-term partnership with AstraZeneca to supply innovative new devices and sensors to incorporate within global patient support programs for patients with COPD and asthma. The Smartinhaler™ platform has so far been used in 63 projects (clinical, device validation or other) and has been referenced in 33 peer reviewed journal articles. The Company has received FDA 510(k) notifications for clearance to market and CE Marks for its devices and software, which allows it to sell these devices into international markets.
James Hattersley will lead Adherium’s partnering and market expansion in North America and will operate out of the newly incorporated U.S. entity. He joins Adherium following his previous appointment at U.S. biopharmaceutical company, Nektar Therapeutics, where he was Vice President of Business Development.
“Establishing operations in North America is a key milestone for Adherium and we look forward to James’ leadership in building our presence in the region as we expand our global footprint,” said Garth Sutherland, CEO of Adherium. “James brings a proven track record of identifying and executing commercial partnerships. His range of business expertise will be instrumental to our North American operations as we work to bring the benefits of digital medical data to more patients, healthcare professionals and payers, enabling better management of chronic disease.”
Source: Globe Newswire